Clinical trials: Monoclonal Antibody
Breast Cancer
Assessment of TK006 in Patients With Breast Cancer-related Bone Metastases
This is a single-center, open-label, dose-escalating study to evaluate the safety, pharmacokinetics, immunogenicity, and preliminary efficacy of single and multiple subcutaneous injection TK006 in patients with breast…
- Trial name
- NCT03239756
- Testing
- TK006
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Jiangsu T-Mab Biopharma Co.,Ltd
Head and Neck Squamous Cell Carcinoma
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
This study is a phase II clinical study to explore the efficacy and safety of BL-B01D1 + PD-1 monoclonal antibody combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma…
- Trial name
- NCT06437522
- Testing
- BL-B01D1, PD-1 monoclonal antibody
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Diffuse Large B-cell Lymphoma
RHCACD20MA (HS006) Combined With CHOP (Hi-CHOP) in Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Primary objective: To evaluate the efficacy of recombinant human-mouse chimeric anti-CD20 monoclonal antibody injection(HS006) with CHOP(Hi-CHOP) versus Rituximab with CHOP (R-CHOP) in patients with previously untreated Diffuse…
- Trial name
- Hi-CHOP (NCT03485118)
- Testing
- HS006+CHOP, Rituximab+CHOP
- Volunteers
- 137 people
- Sponsor
- Zhejiang Hisun Pharmaceutical Co. Ltd.
Chronic Rhinosinusitis With Nasal Polyps
A Study to Evaluate the Efficacy and Safety of MG-K10 in Adults With Chronic Rhinosinusitis With Nasal Polyps
This study aims to evaluate the efficacy and safety of MG-K10 humanized monoclonal antibody injection in the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP).
- Trial name
- NCT07903194
- Testing
- MG-K10, Mometasone Furoate Nasal Spray
- Volunteers
- 210 people
- Sponsor
- Shanghai Mabgeek Biotech.Co.Ltd
Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Unspecified Childhood Solid Tumor, Protocol Specific
IMC-A12 in Treating Young Patients With Relapsed or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor or Other Solid Tumor
This phase I clinical trial is studying the side effects and best dose of IMC-A12 in treating young patients with relapsed or refractory Ewing sarcoma/peripheral primitive neuroectodermal tumor or other solid tumors.
- Trial name
- NCT00609141
- Testing
- cixutumumab, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Liver Metastases, Recurrent Colon Cancer
Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery
RATIONALE: Drugs used in chemotherapy, such as floxuridine and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Liver Metastases, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer
- Trial name
- NCT00645710
- Testing
- gemcitabine hydrochloride, floxuridine, proteomic profiling
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- City of Hope Medical Center
Rheumatoid Arthritis
A Study to Assess the Safety and Efficacy of Adalimumab When Added to Inadequate Standard Anti-Rheumatic Therapy in Patients With Active Rheumatoid Arthritis
This is an open-label, multi-center study in which adalimumab (D2E7) is administered subcutaneously 40 mg every other week in addition to current anti-rheumatic therapies.
- Trial name
- ReAct (NCT00448383)
- Testing
- adalimumab
- Volunteers
- 6,610 people
- Sponsor
- Abbott
Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma
Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
This phase I trial is studying the side effects and best dose of cixutumumab when given together with sorafenib tosylate in treating patients with advanced liver cancer.
- Conditions
- Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Liver Carcinoma, Recurrent Adult Liver Carcinoma
- Trial name
- NCT01008566
- Testing
- Cixutumumab, Laboratory Biomarker Analysis, Sorafenib Tosylate
- Where
- 6 sites in United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma
Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting
The main goal of this study is to evaluate the antitumor activity of relatlimab and nivolumab in combination in subjects with unresectable or metastatic melanoma who have not received prior treatment with immunotherapy.
- Trial name
- NCT03743766
- Testing
- Relatlimab, Nivolumab, Relatlimab + Nivolumab
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- John Kirkwood
Hypereosinophilic Syndrome
Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome
This study will examine the safety and effectiveness of a single dose of anti-interleukin-5 antibody (SCH 55700) in reducing the number of eosinophils (a type of white blood cell) in patients with hypereosinophilic syndrome.
- Trial name
- NCT00017862
- Testing
- SCH55700
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Immune System Disorder
Safety, Pharmacokinetics, and Preliminary Efficacy of Isatuximab in Patients Awaiting Kidney Transplantation
Primary Objectives: Phase 1: To characterize the safety and tolerability of isatuximab in kidney transplant candidates. Phase 2: To evaluate the efficacy of isatuximab in desensitization of participants awaiting kidney…
- Trial name
- NCT04294459
- Testing
- Isatuximab SAR650984, Acetaminophen (paracetamol) or equivalent, Ranitidine or equivalent
- Where
- 6 sites in United States, Spain
- Volunteers
- 23 people
- Sponsor
- Sanofi
Moderate to Severe Chronic Plaque Psoriasis
Phase IIa Study of Multiple Doses of AbGn-168H by iv Infusion in Moderate to Severe Chronic Plaque Psoriasis Patients
This is a Phase IIa, randomised, double-blind, placebo-controlled, multiple dose, multi-center study of AbGn-168H in subjects with moderate to severe chronic plaque psoriasis.The objectives of this study is to investigate…
- Trial name
- AbGn-168H (NCT01855880)
- Testing
- AbGn-168H
- Where
- 15 sites in United States
- Volunteers
- 54 people
- Sponsor
- AbGenomics B.V Taiwan Branch
Hodgkin Lymphoma
A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma
This open-label, randomized, 2-arm, multicenter, phase 3 study has the primary objective of comparing the modified progression-free survival (mPFS) obtained with brentuximab vedotin (ADCETRIS®) plus AVD (doxorubicin [Adriamycin]…
- Trial name
- NCT01712490
- Testing
- brentuximab vedotin, doxorubicin, bleomycin
- Where
- 215 sites in United States, Australia and 19 more
- Volunteers
- 1,334 people
- Sponsor
- Takeda
Coronavirus Disease 2019 (COVID-19)
A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, for Pre-exposure Prophylaxis of COVID-19
A Phase II Randomized, Open-label, Multicenter, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, a Combination…
- Trial name
- ENDURE (NCT05375760)
- Testing
- AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061])
- Where
- 16 sites in United States
- Volunteers
- 251 people
- Sponsor
- AstraZeneca
Breast Cancer
Monoclonal Antibody Therapy Plus Cyclosporine and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Breast Cancer
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00003920
- Testing
- filgrastim, cyclosporine, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of California, Davis
Rh Disease
Pharmacokinetics and Safety of Roledumab in RhD-negative Pregnant Women Carrying an RhD-positive Foetus
The aim of this study is to assess the pharmacokinetic profile of Roledumab 300μg IM / IV in RhD-negative pregnant women carrying an RhD-positive foetus.
- Trial name
- NCT02287896
- Testing
- ROLEDUMAB
- Where
- 8 sites in France
- Volunteers
- 62 people
- Sponsor
- Laboratoire français de Fractionnement et de Biotechnologies
Multiple Myeloma
A Open-Label Phase in Participants With Multiple Myeloma
This is an open-label, multi-center phase II study of IBI3003 in combination with anti-CD38 monoclonal antibody in adult subjects with multiple myeloma.
- Trial name
- NCT07764861
- Testing
- Dexamethasone, IBI3003, Lenalidomide
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Metastatic Melanoma, Unresectable Melanoma
A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma
This is one phase III, randomized, open-label study in comparison of JS001 with dacarbazine as the 1st-line therapy for adult (≥18 years) subjects with unresectable or metastatic melanoma.
- Trial name
- JS001 (NCT03430297)
- Testing
- JS001 240mg Q2W, Dacarbazine 1000mg/m2 Q3W
- Where
- 11 sites in China
- Volunteers
- 256 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Peripheral Spondyloarthritis
Study of Adalimumab in Participants With Peripheral Spondyloarthritis (SpA)
The objective of this study was to evaluate the efficacy and safety of adalimumab 40 mg administered every other week (eow) subcutaneously (SC) compared to placebo for 12 weeks followed by open label (OL) safety and efficacy…
- Trial name
- NCT01064856
- Testing
- Adalimumab
- Volunteers
- 165 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Lymphoma
S8809-S9800-S9911TM- Biological Markers in Patients With Follicular Lymphoma Treated on Clinical Trial SWOG-8809, SWOG-9800, or SWOG-9911
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors predict how patients respond to treatment.
- Trial name
- NCT00896922
- Testing
- microarray analysis, immunohistochemistry staining method, laboratory biomarker analysis
- Volunteers
- 180 people
- Sponsor
- SWOG Cancer Research Network
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.